A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

Albert Grinshpun, Hila Fruchtman, Irit Merlet, Dean Nachman

We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system.

2020

Pneumonia, Metastatic breast cancer, palbociclib, CDK4/6 inhibitors, COVID-19

DOI: 10.3389/fonc.2020.01085

Frontiers in Oncology

Frontiers Media S.A.

Neoplasms. Tumors. Oncology. Including cancer and carcinogens